Logo
S

Spyre Therapeutics

69 employees

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

Investor insights

Funding rounds participated in

$200M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2023

Funding rounds raised

Total raised

$200M

from investors over 1 rounds

S

Spyre Therapeutics raised $200M on December 18, 2024

FAQ